Company intelligence / Profile preview

Burli

Cambridge, Cambridgeshire, United Kingdom

Ownership: Private
Development stage: Other

Overview

Burli is an early-stage biotechnology company focused on the discovery and development of small molecule therapeutics that target RNA. The company leverages a proprietary platform to identify and optimize small molecules capable of binding to specific RNA structures and sequences, aiming to modulate disease-driving pathways that were previously considered undruggable. Burli's research is primarily directed toward high-unmet-need areas, including neurodegenerative disorders and oncology. By targeting the functional transcriptome, the company seeks to create a new class of oral, brain-penetrant medicines.

Therapeutic areas: OncologyNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Burli.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Burli.

Explore the full profile